SynthesisFrontiers in immunology2026
Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To systematically assess the prognostic significance of baseline Methods: A systematic search of five core databases was conducted up to March 2026. Relevant data concerning NSCLC patient characteristics, metabolic [ Results: A total of 33 studies were eligible for inclusion. Univariable analysis showed no prognostic value for SUVmax and SUVmean. Conversely, elevated MTV and TLG were associated with inferior PFS (MTV: HR = 1.71,95% CI: 1.39-2.11; TLG: HR = 1.84, 95%CI: 1.31-2.57) and OS (MTV: HR = 1.80, 95%CI: 1.40-2.33; TLG: HR = 1.92, 95%CI: 1.18-3.12) ( Conclusion: Baseline MTV is an independent prognostic factor for PFS and OS in NSCLC patients treated with ICIs, with a cut-off value within the range of 50-100 cm³ demonstrating optimal predictive performance. In contrast, the predictive significance of TLG for OS was not maintained after multivariable adjustment. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261375745, identifier CRD420261375745.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.